OABI OmniAb Corp Earnings per share for the last twelve months

Corporate company logo of OmniAb, Inc. (OABI)

OmniAb, Inc. (OABI) is in an expansion phase, developing cutting-edge tools for antibody discovery. An efficient IT infrastructure optimizes data flows, thereby increasing margins. The licensing model enables revenue scaling through royalties without incurring production costs. The change in the rolling net income per share demonstrates the dynamics of equity earnings, where -0.34 represents the current level of this metric.

OmniAb, Inc. (OABI) - Earnings per share for the last four quarters from 04/28/2023 to 11/18/2026

Analytical breakdowns and data insights for company OmniAb Inc (OABI)

- stock price and consensus target price:
Initial company analysis:OABI - OmniAb Corp
Mass-produced product of OmniAb Corp

Finding a balance between operational risks and return on capital at OmniAb, Inc. (OABI) requires analyzing the efficiency of AI antibody discovery platforms through the lens of net income. The rolling 12-month net income per share strips the financial result of the impact of share issuance, allowing investors to assess the business's actual profitability trajectory and confirm the company's fundamental stability.